PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Lymphoepithelioma-like carcinoma (LELC) may benefit from immunocheckpoint inhibitor therapy.
Although target antibody drugs for PD-1 and PD-L1 have achieved good results in immunotherapy
of many malignant tumors, there is still a lack of corresponding clinical research reports on
whether LELC treatment can benefit. Therefore, this study intends to adopt the basket
research model , to explore the application of anti-procedural death receptor 1 (PD-1)
monoclonal antibody in patients with advanced LELC after the failure of first-line standard
treatment . Further explore the relationship between tumor and body immunity, tumor
microenvironment and curative effect, and find stable biomarkers, so as to screen out the
superior population of tumor immunotherapy.
Phase:
N/A
Details
Lead Sponsor:
Guangzhou University of Traditional Chinese Medicine